Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has completed dosing for 36 subjects in its human clinical oral nicotine study: NIC-H22-1. According to the announcement, the study is the result of the focus Lexaria has had for years on oral nicotine formulations as an alternative to vaping or smoking; the company noted that results from the study could lead to more rapid commercial adoption and distribution of its patented DehydraTECH(TM) absorption technology, which is designed to improve oral uptake. Statistics show that some 7 million people die every year from cigarette smoking, and alternatives for nicotine delivery are desperately needed. Lexaria’s DehydraTECH-nicotine is already patent granted for oral nicotine delivery in Australia and pending in numerous other countries. The company noted that its DehydraTECH-powered purified nicotine white pouch formulation contains no tobacco, and studies show that its DehydraTECH-nicotine can be 10 to 20 times fast and deliver up to tenfold higher levels of nicotine into blood plasma from oral absorption than concentration-matched controls. LEXX’s NIC-H22-1 study is a human pharmacokinetic randomized, double-blinded, cross-over study with a minimum of 36 human volunteers who currently smoke cigarettes. The study objectives include determining the quantity of nicotine in blood at various time points and collecting vital-sign data, such as blood pressure, heart rate and respiratory rate; Lexaria will provide further updates and any relevant material findings as they become available.
To view the full press release, visit https://cnw.fm/TsuJz
About Lexaria Bioscience Corp.
Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 28 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.canadiancannabiswire.com
Do you have a questions or are you interested in working with CNW? Ask our Editor
CanadianCannabisWire is part of the InvestorBrandNetwork.